In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

The bipartisan bill requires the IEDC to be more transparent when it makes large land purchases for major projects like the ...

Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.

Therini Bio intends to commence two Phase 1b trials imminently, evaluating THN391 for the treatment of patients with Alzheimer’s Disease and Diabetic Macular Edema.

The $160 billion fund behind Ozempic-maker Novo Nordisk A/S says President Donald Trump’s tariff war has created so much ...

Gerhard Koenig, PhD, CEO of Augustine added: "I look forward to working with both Virginie and Andy, whose skills will be invaluable as we advance our lead program into the clinic and further build ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced the company will present data on its ...

Hoofprint Biome, a startup reshaping the cattle microbiome to cut methane emissions and boost yields, today announced the closing of a $15M Series A. The round was led by SOSV, with participation from ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.